OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOncoSil Medical Limited
About this trial
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.
Eligibility criteria
Qualifiers
Patients who are eligible for and undergo OncoSil™ implantation at an eligible treatment facility according to the approved OncoSil™ System Instructions for Use (IFU), as part of their clinical care.
Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPRItaly Patient Registry.
Disqualifiers
Patients participating in an interventional clinical study (company or investigator-sponsored).
Use of an investigational agent at the time of enrolment.
Trial design
Treatments tested in this trial
- OncoSil
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov